Palm Springs fertility clinic bombing: How disaster was averted
Christy Holstege, the former mayor of Palm Springs who is 18 weeks pregnant, was playing with her pre-schooler in their living room Saturday morning when a blast reverberated through her neighborhood and a plume of smoke began to grow on the horizon. It didn't take long for word to reach her that the building ablaze was the local fertility clinic.
Panic gripped Holstege as she thought of her last remaining embryo stored inside the clinic and her concern deepened as she considered the safety of the staff that had carried her family through the last five years of in-vitro fertilization treatment – first with her son and again this year.
Through a fortuitous turn of events, the usually bustling American Reproductive Center was completely empty when a car exploded outside the clinic Saturday, blowing a gaping hole in the side of the building and severing the power supply of the lab where thousands of embryos and other specimens are stored.
For miles around the blast zone, Coachella Valley families held the babies and toddlers conceived at ARC. Alongside hopeful would-be parents, they worried for the immediate fate of their remaining embryos in the clinic, and for the long-term safety of the reproductive center, which authorities believe was targeted in an act of domestic terrorism.
Mothers Sophie and Simone Bain-Tohl were hosting a party full of fellow parents when they heard news of the attack. The room grew somber as they surrounded a play mat full of wriggling babies – two of them conceived by IVF – and realized every person in the room either had embryos stored at ARC or knew someone who does.
Though the frozen embryos at the clinic would remain cold without electricity, a set of embryos being incubated would be irreversibly damaged if power was not restored within hours.
But at the scene of the explosion, a firefighter began to hatch a risky plan to protect future families, including that of a fellow first responder.
Firefighters initially rushed to tamp down the blaze caused by the explosion and ensure no victims were inside. But the crumbling building soon began to shift and bomb squad technicians became concerned about a possible secondary device that could put first responders at risk.
When Deputy Fire Chief Greg Lyle arrived an hour after the blast, first responders had been ordered to get out of the still smoking building until a bomb squad could assess the scene.
Clinic director Dr. Maher Abdallah, who was able to access clinic security cameras before the power went out, reported that the embryo lab appeared intact, but Lyle was not convinced. Itching to help, he and the other firefighters began considering how they could ensure the embryo incubators and cryogenic tanks were secure.
'So I went over to the lead FBI investigator, and kind of pitched a crazy scheme to him, fully expecting him to say no,' Lyle said.
The scheme: Lyle would venture alone into the still standing part of the building, which contained unknown risk of structural collapse, a secondary explosion or additional fires, to find the lab and assess the status of the embryos.
'This is a crazy plan, and if anybody's going to get hurt, the only thing that I would be able to be comfortable with is that it would be me,' he said. 'I just had a gut feeling it had to be me.'
The FBI agent, identified by the city police chief as Agent Chris Meltzer, embraced the plan under one condition: Meltzer would accompany Lyle.
Together, the pair headed into the building, cautiously navigating blown-out door frames, crumbling drywall and several inches of standing water, likely from a water main break or fire sprinklers. They eventually spotted a room stacked with what appeared to be cryogenic tanks.
'We thought initially that maybe we could go in and just grab it and go. But it was obvious there was too much (equipment) – too big, too bulky, too heavy,' Lyle said. 'So we determined the only thing we could do would be restore power to this stuff.'
Quickly, they realized the backup generators had failed, and it became increasingly clear they alone would not be able to restore the electricity. The pair picked their way back out of the building to assemble a team of firefighters, police and bomb squad personnel to address the outage.
'It took them a while, but they were successful,' Lyle said.
The team's heroic initiative likely saved the incubating embryos, Abdallah said. An hour or two longer without power could have had tragic consequences.
Unbeknownst to Lyle, the ARC lab houses embryos belonging to the wife of one of his own firefighters, who sent Lyle a message thanking him for preserving his family's future.
'It kind of hit home there. I didn't even know,' Lyle said. The firefighter's wife is among the patients with appointments early this week.
Yet, in order to continue ongoing treatment for patients, it would take a second team effort to keep the delicate process moving forward.
Most Saturdays, Abdallah and his staff are flitting between patient rooms and laboratories, sterilizing equipment, checking on growing embryos and walking hopeful parents through the arduous process of in vitro fertilization.
But through a series of inexplicable events, the clinic was completely empty on Saturday when the car exploded outside.
Abdallah had spontaneously decided to visit family. Two other weekend employees had been called away. And the clinic, just days before, had rescheduled a procedure that would have required 12 employees to be in the office at the time of the explosion.
'So many things happened to protect our staff,' Abdallah said. 'It's just really a miracle.'
Though shaken by the bombing, Abdallah and his staff have been seeking solace in each others' presence and their shared determination to continue operating the clinic.
The attack, though unsuccessful, delivered a seismic shock to patients and violated a space that many feel is far more intimate than just a medical clinic; It's the venue where their families were formed and precious possibilities are stored.
'I went there every week for the last 12 weeks, sometimes twice a week,' Holstege said. 'That is my home, my medical home.'
As the only fertility clinic within a 100-mile radius, ARC stores thousands of embryos, eggs and sperm specimens for patients from Palm Springs to as far as Asia and the Middle East, Abdallah said.
Several families who depend on ARC for fertility services described a profound level of care from the clinic's staff, who have made late-night calls to share test results, scheduled extra ultrasounds for nervous mothers and held patients in their arms during moments of both grief and joy.
'ARC is a place where we went to build our family and holds so much more than just a clinic. It's a place of vulnerability and hope and tenderness, and the staff there is just incredible,' said Sophie Bain-Tohl, whose four-month-old son was conceived at ARC.
Though Bain-Tohl and her wife plan to keep their embryos at ARC, the attack has left them with a lingering fear for the safety of their embryos, which they hope will one day provide them with a daughter.
'Our sense of safety is shattered by something like this,' Simone Bain-Tohl said. 'It's such an absurd event that you never really think it's going to happen, especially to a place that's tied to so much hope and vulnerability.'
Investigators say the 25-year-old bombing suspect, who was killed in the blast, had 'nihilistic ideations' and intentionally targeted the IVF facility – a reality that Holstege and other patients are having difficulty coming to terms with.
'Why would someone do this? Who could do this? This is a place of hope and creating life,' said Holstege.
For some patients with appointments in the days following the explosion, halting treatment is simply not an option, Abdallah explained. The window for egg retrieval and embryo transfer is very tight and delaying care would mean starting the entire process over again – risking time and money many couples do not have.
Less than 24 hours after the bombing, Abdallah was formulating a plan to continue providing time-sensitive treatment to these patients, which required retrieving their valuable medical records from inside the most heavily damaged part of the clinic.
Again, a crew of fire personnel and other law enforcement entered the compromised building.
'We needed a team of people to kind of bucket brigade all these folders out of the building,' Lyle said. Abdallah also asked them to haul out two brand new ultrasound machines.
'I was just really amazed at the risk they're willing to take, and how they just work so well together,' the clinic director said.
As the clinic races to rebuild, Abdallah is determined to continue providing care. On Monday, his staff saw patients in a room loaned to them by a fellow physician.
But the emotional trauma experienced by his patients and staff is not lost on Abdallah, whose office is holding a news conference Thursday to update the community on its plans for 'moving forward with strength and renewed purpose.'
'The patients who have embryos, a lot of them regard those embryos as children,' he said. 'They go through so much to get to that point where their embryos are frozen. They need a lot of reassurance to know that their embryos are safe.'
See Full Web Article
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
5 hours ago
- Yahoo
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival
Yahoo
6 hours ago
- Yahoo
State Department Halts Medical Visas For Palestinians
Eight Palestinian children from Gaza named, Rahaf, Ibrahim, Jana, Mustafa, Nasser, Mohammed, Kenan, and Ahmed, arrive at O'Hare International Airport, sponsored by Palestine Children's Relief Fund (PCRF), for medical treatment in Chicago, Illinois, USA on December 2, 2024. Credit - Jacek Boczarski—Anadolu via Getty Images The State Department said it would stop issuing visas to Palestinians from Gaza, including to those coming to the United States for humanitarian and medical treatment, following a campaign by far-right political activist Laura Loomer. 'All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days,' the U.S. State Department said in a statement on Saturday. The decision will impact several programs that have evacuated dozens of critically injured children from Gaza over the last 21 months, including amputees and severe burn victims. The announcement came just hours after a series of social media posts from Loomer criticizing the medical evacuations of Palestinian children to the U.S. In one post, she shared a video of a child amputee arriving in a wheelchair at Seattle airport for medical treatment, adding: 'The Trump administration needs to shut this abomination down ASAP.' Loomer, who once described herself as a 'proud Islamaphobe' and said 9/11 was an 'inside job,' made false claims in her posts and said she had sent her 'evidence' to Secretary of State Marco Rubio. Hours later, the pause was announced. Read more: I Can No Longer Feed Kids in Gaza Rubio told "Face the Nation" on CBS on Sunday that the action came after "outreach from multiple congressional offices asking questions about it." But Loomer quickly took credit for the pause, posting: 'It's amazing how fast we can get results from the Trump administration.' The Palestinian Children Relief Fund (PCRF), a charity that organizes medical evacuations of children to the U.S., said the move will prevent them from providing 'lifesaving medical treatment' for 'critically ill children' from Gaza. 'Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza,' the PCRF said in a statement. According to the World Health Organization (WHO), Gaza's health system has been in collapse, and there has been a 'relentless and systematic decimation of hospitals in Gaza.' The United Nations children's charity, UNICEF, said in July that more than 17,000 children have been killed and 33,000 injured in Gaza in the last 21 months. HEAL Palestine, another charity that organizes evacuations and which was specifically targeted by Loomer in her posts, said this month it has evacuated 63 injured children and 148 total evacuees to the U.S. to receive treatment. Earlier this month, it carried out the largest known evacuation of wounded children from Gaza to the U.S., which included 11 children and their families, most of them for treatment of amputations. HEAL Palestine made it clear on social media that the visas it uses to bring people to the U.S. for treatment were not for resettlement, but for lifesaving care, contrary to Loomer's claims. 'After their treatment is complete, the children and any accompanying family members return to the Middle East. This is a medical treatment program, not a refugee resettlement program,' HEAL Palestine said Saturday. The charity added that U.S. tax dollars do not fund the treatment provided to these children. Loomer, a conspiracy theorist with a history of using hate speech to gain attention, has acquired an outsized influence over the White House in President Donald Trump's second term. She has successfully lobbied to remove people from top government roles whom she considers disloyal to the president, including six from the National Security Council, a senior Customs and Border Protection official, and a Food and Drug Administration vaccine official. TIME has contacted the State Department for comment. Contact us at letters@ Solve the daily Crossword